CD40 and neoplasm: Given that numerous antitumor strategies including checkpoint inhibitor treatments are less sensitive to PDAC, the combined therapeutic method by inducing tumor-specific T cells via DC vaccination and remodeling the desmoplasia of the tumor microenvironment (TME) via CD40-agonistic antibody administration could reduce the tolerance to PDAC.